The biggest misconception that we run into when using amino acid therapy is how to interpret urinary neurotransmitter results. This post should help clear up some of that confusion.
We have been working with conditions associated with neurotransmitter imbalance for over two decades. During that time, we have learned a good deal about the most effective strategies to restore optimal neurotransmitter function. One of the most profound discoveries was determining the best way to address the different neurotransmitter systems in the body.
In 2014, Mary Hinz, MD, et al, published a paper that hypothesized that carbidopa depleted the body of vitamin B6 and that this decrease in B6 levels led to progressive neurodegeneration in patients with Parkinson’s disease. Two recent papers provide additional evidence that seems to support that assertion.
I’ve had several clients inquire about the amount of carbohydrates in the Mucuna powder that we use and whether that will affect their ability to follow a ketogenic diet and stay in ketosis, so I thought this an opportune time to address this issue in a post.
Most of the time when we think about neurological disorders and how to manage them, we often think about targeting the brain. Resent research indicates that we may want to include investigations of the microbial environment in the gut to uncover each person’s root imbalances.
